Schizophrenia Database

The current version of the database includes clinical safety and efficacy information on both second-generation antipsychotics (SGAs) currently approved or in development for the first-line monotherapy treatment of schizophrenia and on anti-psychotics used for the second-line treatment (monotherapy or add-on) in treatment-resistant or refractory schizophrenia patients. Information on first-generation antipsychotics (FGAs) such as haloperidol are included if they were used as active controls.

The schizophrenia database has recently been updated. The updated database contains information on 137 unique trials, representing 390 unique treatment arms and about 32,700 patients. Download an information sheet for the Schizophrenia database.